Physiological Dissection of the Mevalonate Pathway

甲羟戊酸途径的生理解剖

基本信息

  • 批准号:
    10359805
  • 负责人:
  • 金额:
    $ 53.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-06 至 2024-02-29
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Statins are the only lipid lowering agents consistently shown to reduce the risk of death from cardiovascular disease as a monotherapy. Currently, it is estimated that greater than 39.2 million adults in the United States are on statins, and new may further increase the number of users in the U.S. alone to 56.0 million. This underscores the importance of understanding the genetic basis of statin responsiveness as well as adverse events. Statins act primarily in the liver by inhibiting 3-hydroxy-3-methylglutaryl Coenzyme A reductase (Hmgcr), the rate-limiting enzyme in the mevalonate pathway. In addition to cholesterol, the mevalonate pathway also produces other essential molecules including: isopentenyl tRNA, heme A, ubiquinone, dolichol, farnesylated and geranylgeranylated proteins, and vitamin K2. Despite over three decades of research, development, and clinical experience with statins, many unanswered questions remain about the physiological role and regulation of the mevalonate pathway in the liver. Critical gaps in knowledge include: 1) which nonsterol metabolites are most sensitive to depletion, 2) the necessity of the different mevalonate-derived metabolites for hepatocyte function, 3) the precise identity of nonsterol regulatory molecules, 4) genetic factors that determine individual variation in LDL-C lowering, and 5) the mechanisms by which statins increase the risk of type II diabetes. Our long-term goal is understand the physiological mechanisms controlling the mevalonate pathway and statin responsiveness, in order to enable personalized medicine and identify new drug targets. We propose three Specific Aims: 1) Define which isoprenoid products are required for hepatocyte viability in vivo, 2) Test the hypothesis that loss of dolichol is responsible for ER stress-induced apoptosis during potent Hmgcr inhibition, 3) Determine the physiological effects of statins on human hepatocytes in vivo. Successful completion of these studies will define the essential mevalonate-derived metabolites in the liver, and improve our understanding of new genes and pathways underlying statin-related hepatotoxicity and statin responsiveness.
项目总结 他汀类药物是唯一一直被证明可以降低心血管死亡风险的降血脂药物 疾病作为一种单一疗法。目前,据估计,美国有超过3920万成年人是 在他汀类药物方面,NEW可能会进一步将仅在美国的用户数量增加到5600万。这强调了 了解他汀类药物反应性的遗传基础以及不良事件的重要性。他汀类药物 主要通过抑制3-羟基-3-甲基戊二酰辅酶A还原酶(Hmgcr)在肝脏发挥作用,Hmgcr是限速酶 甲氧戊酸途径中的酶。除胆固醇外,甲氧戊酸途径还会产生其他 基本分子包括:异戊烯基tRNA、血红素A、泛醌、二苯二酚、法尼化和 香叶基香叶蛋白和维生素K2。尽管经过了三十多年的研究、开发和临床 关于他汀类药物的经验,关于他汀类药物的生理作用和调节仍有许多悬而未决的问题。 甲氧戊酸在肝脏中的途径。知识方面的关键差距包括:1)哪些非甾醇代谢物最多 对消耗敏感,2)甲氧戊酸衍生的不同代谢物对肝细胞功能的必要性, 3)非固醇调节分子的精确识别,4)决定个体差异的遗传因素。 降低低密度脂蛋白,以及5)他汀类药物增加II型糖尿病风险的机制。我们的长期目标 了解甲氧丙戊酸途径和他汀类药物反应的生理机制 以实现个性化药物和识别新的药物靶点。我们提出了三个具体目标:1)定义 体内肝细胞存活所需的类异戊二烯产物,2)检验二氢异戊二烯丢失的假设 在内质网应激诱导的细胞凋亡过程中对Hmgcr有很强的抑制作用,3)决定生理性的 他汀类药物对活体人肝细胞的影响。成功完成这些研究将确定必要的 肝脏中甲氧戊酸衍生的代谢物,并提高我们对新基因和新途径的理解 潜在的他汀类药物的肝毒性和他汀类药物的反应性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Raymond Lagor其他文献

William Raymond Lagor的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William Raymond Lagor', 18)}}的其他基金

Genome Editing and Biological Effects Testing Section
基因组编辑及生物效应检测组
  • 批准号:
    10773478
  • 财政年份:
    2023
  • 资助金额:
    $ 53.21万
  • 项目类别:
Physiological Dissection of the Mevalonate Pathway
甲羟戊酸途径的生理解剖
  • 批准号:
    10579186
  • 财政年份:
    2020
  • 资助金额:
    $ 53.21万
  • 项目类别:
Genetic Repair of Familial Hypercholesterolemia
家族性高胆固醇血症的基因修复
  • 批准号:
    10444520
  • 财政年份:
    2016
  • 资助金额:
    $ 53.21万
  • 项目类别:
Genetic Repair of Familial Hypercholesterolemia
家族性高胆固醇血症的基因修复
  • 批准号:
    10588157
  • 财政年份:
    2016
  • 资助金额:
    $ 53.21万
  • 项目类别:
Genetic Repair of Familial Hypercholesterolemia
家族性高胆固醇血症的基因修复
  • 批准号:
    10063884
  • 财政年份:
    2016
  • 资助金额:
    $ 53.21万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.21万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.21万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 53.21万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.21万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.21万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.21万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.21万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 53.21万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 53.21万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 53.21万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了